Rhythm Pharmaceuticals Inc [RYTM] stock prices are up 1.29% to $100.69 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The RYTM shares have gain 3.13% over the last week, with a monthly amount drifted -8.70%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on November 05, 2025, when Oppenheimer downgraded its rating to a Perform. Previously, Goldman started tracking the stock with Buy rating on July 10, 2025, and set its price target to $97. On July 07, 2025, Leerink Partners initiated with an Outperform rating and assigned a price target of $88 on the stock. BofA Securities upgraded its rating to a Buy but stick to its price target of $63 on April 07, 2025. Jefferies started tracking with a Buy rating for this stock on January 02, 2025, and assigned it a price target of $80. In a note dated December 20, 2024, Oppenheimer initiated an Outperform rating and provided a target price of $76 on this stock.
The stock price of Rhythm Pharmaceuticals Inc [RYTM] has been fluctuating between $45.90 and $116.00 over the past year. Currently, Wall Street analysts expect the stock to reach $126 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $100.69 at the most recent close of the market. An investor can expect a potential return of 25.14% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
The Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] reported sales of 174.33M for trailing twelve months, representing a surge of 54.28%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.07%, Pretax Profit Margin comes in at -1.1%, and Net Profit Margin reading is -1.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -1.26 and Total Capital is -0.46. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 99.51 points at the first support level, and at 98.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 101.92, and for the 2nd resistance point, it is at 103.16.
Ratios To Look Out For
It’s worth pointing out that Rhythm Pharmaceuticals Inc [NASDAQ:RYTM]’s Current Ratio is 4.75. On the other hand, the Quick Ratio is 4.53, and the Cash Ratio is 0.5. Considering the valuation of this stock, the price to sales ratio is 38.55, the price to book ratio is 45.12.
Transactions by insiders
Recent insider trading involved Cramer Pamela J., Chief Human Resources Officer, that happened on Nov 07 ’25 when 19351.0 shares were sold. Chief Human Resources Officer, Cramer Pamela J. completed a deal on Nov 10 ’25 to sell 3515.0 shares. Meanwhile, Officer PAMELA CRAMER bought 3515.0 shares on Nov 10 ’25.
